Unlock instant, AI-driven research and patent intelligence for your innovation.

New method for treating type II diabetes through immunity adjustment and control

A modulatory, compound-based technology for biomedical applications that addresses the lack of proof-of-concept studies

Pending Publication Date: 2019-08-30
BIOTHEUS INC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is still a lack of proof-of-concept studies for regulatory T cell-based immunotherapy for type 2 diabetes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New method for treating type II diabetes through immunity adjustment and control
  • New method for treating type II diabetes through immunity adjustment and control
  • New method for treating type II diabetes through immunity adjustment and control

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0207] Example 1: Effect of long-term insulin injection on mouse insulin sensitivity

[0208] In this example, wild-type mice received daily intraperitoneal injection of PBS or insulin (0.5 U / Kg) for two months.

[0209] The result is as figure 1 Insulin injection in vivo can induce a large amount of CD73 low Adipose regulatory T cells. CD73 expression was greatly suppressed in insulin-injected mouse adipose regulatory T cells, but CD39 levels remained largely unchanged (Fig. 1a–c).

[0210] Further, glucose tolerance test (GTT) and insulin tolerance test (ITT) were performed on mice to study CD73 low Relationship between fat regulatory T cells and insulin sensitivity. The results showed that insulin-treated mice had greater blood glucose fluctuations and impaired insulin sensitivity (Fig. 1d). Thus, these data suggest that chronic insulin injection induces the accumulation of CD73 low Adipose regulatory T cells and cause insulin resistance.

Embodiment 2

[0211] Example 2: CD73 low and CD73 hi A Comparison of the Suppressive Ability of Adipose Regulatory T Cells

[0212] CD4 sorting from wild-type mice + CD25-YFP-Teff cells labeled with CellTrace Violet dye. and compared it with CD4 sorted from wild-type mice + CD25 hi YFP + CD73 hi Adipose regulatory T cells or CD4 + CD25 hi YFP + CD73 low Adipose regulatory T cell co-culture. The cell mixture system was stimulated with anti-CD3 / CD28 antibody-coupled magnetic beads, and the proliferation of responding cells was measured three days later. Afterwards, the proportion of responding Teff cells proliferating was further measured.

[0213] The result is as figure 2 As shown in a-d, in vitro tests suggest that CD73 hi Adiporegulatory T cells were more suppressive (Fig. 2a,b), indicating their protective effect on adipose inflammatory responses. In addition, CD73 low Fat-regulated production of large amounts of the inflammatory factor IFN-γ exhibited a phenotype resemb...

Embodiment 3

[0217] Example 3: Adenosine or Adenosine Receptor A 2A Effects of receptor agonists on cells

[0218] In this example, adenosine or adenosine receptor A 2A Th1 cells and undifferentiated M0 macrophages were directly treated with receptor agonists to test the direct effect of these two small molecules on the cells.

[0219] The result is as image 3 Indicated, adenosine (10 μM) or adenosine receptor A 2A After Th1 cells were directly treated with receptor agonist (1 μM), the cells secreted less inflammatory cytokines IL-2 and IFN-γ ( image 3 a-c), suggesting that this inhibitory effect acts directly on Th1 cells.

[0220] And, adenosine or adenosine receptor A 2A After receptor agonists directly treat M0 macrophages, the cells up-regulate the marker molecule CD206 of M2 macrophages ( image 3 d and e), while macrophages secrete less pro-inflammatory cytokine IL-1β ( image 3 f), secrete more immunosuppressive cytokine IL-10 ( image 3 g).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a new method for treating type II diabetes through immunity adjustment and control, and specifically provides the use of a substance or compound. The substance or the compound is used for preparing a medical composition or preparation. The medical composition or preparation is used for (i) strengthening the sensibility of organisms to insulin, (ii) restraining inflammation,(iii) increasing the proportion of M2 / M1 type macrophagocyte in macrophagocyte in organisms, and / or (iv) restraining the immunity reactions of T cells of the organisms, wherein the substance or the compound is selected from the following groups (a) regulatory T cells of highly-expressed CD73, (b) adenosine, and (c) an adenosine receptor A2A exciting agent, or the combination of (a) the regulatoryT cells of the highly-expressed CD73, (b) the adenosine, and (c) the adenosine receptor A2A exciting agent. The invention further provides a method which can strengthen the sensibility of the organisms to the insulin, restrain the inflammation of the organisms, increase the proportion of the macrophagocyte M2 / M1 in the organisms, and / or restrain the immunity reactions of the organisms. Through theadoption of the method disclosed by the invention, the inflammation can be significantly relieved, and / or the sensibility of cells to the insulin is strengthened.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a new method for treating type II diabetes through immune regulation. Background technique [0002] Diabetes mellitus is a group of syndromes composed of different pathophysiological changes characterized by abnormal glucose metabolism. There is great heterogeneity among different patients. The two main pathophysiological changes are insufficient insulin secretion and insulin resistance. [0003] Approximately 92 million adults now have type 2 diabetes. Although changes in nutritional status and lifestyle, and the increase in the incidence of obesity are important factors leading to the increase in the incidence of type 2 diabetes, genetic factors also play an indispensable role. In the past few decades, the incidence of type 2 diabetes in China has increased significantly. Studies have shown that East Asian populations, including the Chinese Han population, have a higher...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/17A61K31/7076A61K45/06A61P3/10A61P5/50A61P29/00A61P37/02C12Q1/6883
CPCA61K9/0019A61K31/7076A61K35/17A61K45/06A61P3/10A61P5/50A61P29/00A61P37/02C12Q1/6883C12Q2600/158A61K2300/00
Inventor 李斌李扬扬李丹梁瑞
Owner BIOTHEUS INC